Following completion of a successful Phase I study that identified an acceptable safety profile, Myelovax™ is soon opening a Phase 2 study using the vaccine in the post-CAR T setting.

For Phase I data, please read the paper here: An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission